Long-Term Prognostic Value of Neopterin: A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome

Background— Monocyte activation is believed to play an important role in the pathogenesis of acute coronary syndromes (ACS). Neopterin is a soluble marker of monocyte activation, and elevated levels are of prognostic value in patients with stable coronary artery disease. Methods and Results— Neopterin levels were measured on average at 7 days (in 3946 patients) and at 4 months (in 3369 patients) after ACS in the PRavastatin Or atorVastatin Evaluation Infection Therapy–Thrombolysis In Myocardial Infarction (PROVE IT–TIMI 22) trial. We assessed the relationship between plasma neopterin levels and the risk of death and death or acute coronary events (nonfatal myocardial infarction or unstable angina) over 2 years. Seven days after an ACS event, neopterin levels ≥12.11 nmol/L (upper quartile, derived from a post hoc analysis) were associated with an increased risk of death and an increased risk of death or acute coronary events after adjustment for age, gender, history of diabetes mellitus, history of hypertension, history of smoking, type of ACS presentation, use of percutaneous coronary intervention for the index event, statin regimen, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (hazard ratio, 1.86 [95% CI, 1.24 to 2.77], P=0.003; and hazard ratio, 1.33 [95% CI, 1.09 to 1.63] P=0.006, respectively). Neopterin levels ≥12.11 nmol/L at 4 months remained a predictor of death alone and of death or acute coronary events after multivariable adjustment that included adjustment for month 4 low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and statin regimen (hazard ratio, 2.39 [95% CI, 1.43 to 3.99], P=0.001; and hazard ratio, 1.60 [95% CI, 1.21 to 2.11], P=0.001). High-dose atorvastatin significantly attenuated the risk among subjects with neopterin levels ≥12.11 nmol/L at baseline (interaction P for death or acute coronary event, 0.018). Conclusions— Increased monocyte activation detected by an elevated plasma neopterin level identifies patients at long-term risk of death or recurrent acute coronary events after ACS. Intensive statin therapy significantly attenuates the risk of recurrent events among patients with an elevated neopterin level.

[1]  Amy Shui,et al.  Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial , 2006, Circulation.

[2]  W. Padberg,et al.  Post‐Transplant sCD30 and Neopterin as Predictors of Chronic Allograft Nephropathy: Impact of Different Immunosuppressive Regimens , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  W. Howard.  C-Reactive Protein Levels and Outcomes After Statin Therapy , 2006 .

[4]  I. Çelik,et al.  Serum neopterin levels in patients with brucellosis. , 2005, The Journal of infection.

[5]  Nader Rifai,et al.  Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.

[6]  P. Ridker,et al.  Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. , 2005, Journal of the American College of Cardiology.

[7]  J. Fahey,et al.  Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Kaski,et al.  Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. , 2005, European heart journal.

[9]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[10]  J. Kaski,et al.  Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris , 2004, Circulation.

[11]  J. Kaski,et al.  Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes , 2004, Heart.

[12]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[13]  F. Zijlstra,et al.  Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. , 2003, The American journal of cardiology.

[14]  C. Heeschen,et al.  Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes , 2003, Circulation.

[15]  C. Heeschen,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, New England Journal of Medicine.

[16]  E. Antman,et al.  Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.

[17]  D. Fuchs,et al.  Atorvastatin suppresses interferon‐γ‐induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines , 2003, Clinical and experimental immunology.

[18]  D. Fuchs,et al.  HMG-CoA Reductase Inhibitors Are Associated with Decreased Serum Neopterin Levels in Stable Coronary Artery Disease , 2003, Clinical chemistry and laboratory medicine.

[19]  D. Fuchs,et al.  Human parvovirus Bb19 detection in asymptomatic blood donors: association with increased neopterin concentrations. , 2002, The Journal of infectious diseases.

[20]  D. Fuchs,et al.  Factors influencing serum neopterin concentrations in a population of blood donors. , 2002, Clinical chemistry.

[21]  K. Żwirska-Korczala,et al.  Neopterin measurement in clinical diagnosis , 2001, Journal of clinical pharmacy and therapeutics.

[22]  J. Auer,et al.  Serum neopterin and activity of coronary artery disease. , 2001, Heart disease.

[23]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[24]  A. Maseri,et al.  Enhanced Response of Blood Monocytes to In Vitro Lipopolysaccharide-Challenge in Patients With Recurrent Unstable Angina , 2001, Circulation.

[25]  R. Frye,et al.  Molecular Fingerprint of Interferon-&ggr; Signaling in Unstable Angina , 2001, Circulation.

[26]  J. Mege,et al.  Highly Active Antiretroviral Therapy (HAART) and Circulating Markers of Immune Activation: Specific Effect of HAART on Neopterin , 2000, Clinical Diagnostic Laboratory Immunology.

[27]  R. Frye,et al.  Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. , 2000, Circulation.

[28]  J. Kaski,et al.  Serum neopterin and complex stenosis morphology in patients with unstable angina. , 2000, Journal of the American College of Cardiology.

[29]  J. Kaski,et al.  Increased serum neopterin: a marker of coronary artery disease activity in women , 2000, Heart.

[30]  R. Frye,et al.  Perturbation of the T-cell repertoire in patients with unstable angina. , 1999, Circulation.

[31]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[32]  B. Scirica,et al.  Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. , 1999, The American journal of cardiology.

[33]  J. Kaski.  Increased neopterin in patients with chronic and acute coronary syndromes. , 1998, Journal of the American College of Cardiology.

[34]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[35]  P. Hannonen,et al.  Urinary neopterin index as a measure of rheumatoid activity. , 1986, Scandinavian journal of rheumatology.